Loading…
Polaryx Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in PLYX.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PYPDPolyPid Ltd. | $5.07 | — | 19.1x | — | -243.59% | $102.98M |
| LNSRLENSAR, Inc. | $8.30 | 41.5x | 6.8x | — | 357.30% | $101.97M |
| CRDFCardiff Oncology, Inc. | $1.33 | — | 3.4x | — | -94.08% | $103.47M |
| SEERSeer, Inc. | $1.80 |
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Company description provided by Yahoo Finance.
| — |
| 0.4x |
| — |
| -26.45% |
| $99.67M |
| CCLDCareCloud, Inc. | $2.49 | 35.6x | 6.1x | — | 21.75% | $105.81M |
| MBOTMicrobot Medical Inc. | $1.48 | — | 1.4x | — | -32.91% | $99.4M |